Long-term cost-efficacy of rituximab in immune thrombocytopenic purpura.
Pérez-Calvo
J I
JI
Ruiz-Ruiz
F
F
Amores
B
B
Torralba
M A
MA
D000328:Adult; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003362:Cost-Benefit Analysis; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000191:economics; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab